X protein mutations in hepatitis B virus DNA predict postoperative survival in hepatocellular carcinoma

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10325-10331

  Xie, Ying ^a   Liu, Shufeng ^a   Zhao, Yue ^a   Guo, Zhanjun ^a   Xu, Jinsheng ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

HBx; Hepatocellular carcinoma; Mutations; Survival

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS DNA;

ADULT; AGED; COMPLICATION; FEMALE; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; MUTATION; PROPORTIONAL HAZARDS MODEL; VIROLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; TRANS-ACTIVATORS;

EID: 84922394537     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2331-0     Document Type: Article

References (41)

1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300–8
2. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol. 2000;14:703–9
3. Lu FM, Zhuang H.Management of hepatitis B in China. ChinMed J (Engl). 2009;122:3–4
4. Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol. 2007;14:1182–90
5. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 1994;106:1618–24
6. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703–10
7. Wang C, Zhang F, Fan H, Peng L, Zhang R, Liu S, et al. Sequence polymorphisms of mitochondrial d-loop and hepatocellular carcinoma outcome. Biochem Biophys Res Commun. 2011;406:493–6
8. Bartholomeusz A, Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol. 2004;14:3–16
9. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, et al. Associations between hepatitis B virusmutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009;101:1066–82
10. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100: 1134–43
11. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010;29:2309–24
12. Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ, Mok TS: High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177–82
13. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97:265–72
14. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis. 2006;193: 1258–65
15. Lin CL, Liu CH, Chen W, Huang WL, Chen PJ, Lai MY, et al. Association of pre-s deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1098–103
16. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology. 2003;124:327–34
17. Kim DW, Lee SA, Hwang ES, Kook YH, Kim BJ. Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma. PLoS One. 2012;7:e47372
18. Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, et al. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology. 2010;52:1922–33
19. Chen J, Yin J, Tan X, Zhang H, Zhang H, Chen B, et al. Improved multiplex-PCR to identify hepatitis b virus genotypes A-F and subgenotypes B1, B2, C1 and C2. J Clin Virol. 2007;38:238–43
20. Jang JW, Chun JY, Park YM, Shin SK, Yoo W, Kim SO, et al. Mutational complex genotype of the hepatitis b virus x /precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci. 2012;103:296–304
21. Guo X, Jin Y, Qian G, Tu H. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol. 2008;49:718–25
22. Xu L, Qian G, Tang L, Su J, Wang JS. Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. J Hepatol. 2010;53: 671–6
23. Hunt CM, McGill JM, AllenMI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology. 2000;31:1037–44
24. Yip WK, Cheng AS, Zhu R, Lung RW, Tsang DP, Lau SS, et al. Carboxyl-terminal truncated HBx regulates a distinct microrna transcription program in hepatocellular carcinoma development. PLoS One. 2011;6:e22888
25. Sze KM, Chu GK, Lee JM, Ng IO. C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology. 2013;57:131–9
26. Geng X, Harry BL, Zhou Q, Skeen-Gaar RR, Ge X, Lee ES, et al. Hepatitis B virus x protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ increase and cell death in caenorhabditis elegans. Proc Natl Acad Sci U S A. 2012;109:18465–70
27. Kim JK, Chang HY, Lee JM, Baatarkhuu O, Yoon YJ, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH: Specificmutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol. 2009;81:1002–8
28. Khan A, Al Balwi MA, Tanaka Y, Hajeer A, Sanai FM, Al AbdulkarimI, et al. Novel pointmutations andmutational complexes in the enhancer II, core promoter and precore regions of hepatitis B virus genotype D1 associated with hepatocellular carcinoma in Saudi Arabia. Int J Cancer. 2013;133:2864–71
29. Li SK, Ho SF, Tsui KW, Fung KP, Waye MY. Identification of functionally important amino acid residues in the mitochondria targeting sequence of hepatitis B virus X protein. Virology. 2008;381:81–8
30. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus x protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A. 1994;91:2230–4
31. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation ofWnt/beta-catenin signaling in hepatoma cells. Hepatology. 2004;39:1683–93
32. Chung TW, Lee YC, Kim CH. Hepatitis B viral hbx induces matrix metalloproteinase-9 gene expression through activation of erk and pi- 3K/AKT pathways: involvement of invasive potential. FASEB J. 2004;18:1123–5
33. Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 2010;52: 142–54
34. Cho EY, Choi CS, Cho JH, Kim HC. Association between hepatitis B virus X gene mutations and clinical status in patients with chronic hepatitis B infection. Gut Liver. 2011;5:70–6
35. Tian Y, Yang W, Song J, Wu Y, Ni B. Hepatitis B virus X proteininduced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Mol Cell Biol. 2013;33: 2810–6
36. Song K, Han C, Zhang J, Lu D, Dash S, FeitelsonM, et al. Epigenetic regulation of microRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology. 2013;58:1681–92
37. Wu G, Yu F, Xiao Z, Xu K, Xu J, Tang W, et al. Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. Br J Cancer. 2011;105:146–53
38. Qiu X, Dong S, Qiao F, Lu S, Song Y, Lao Y, et al. Hbx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene. 2013;32:3296–305
39. Li MS, Lau TC, Chan SK, Wong CH, Ng PK, Sung JJ, et al. The G1613A mutation in the HBV genome affects HBeAg expression and viral replication through altered core promoter activity. PLoS One. 2011;6:e21856
40. Tangkijvanich P, Sa-Nguanmoo P, Mahachai V, Theamboonlers A, Poovorawan Y. A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int. 2010;4:577–84
41. Donello JE, Beeche AA, Smith 3rd GJ, Lucero GR, Hope TJ. The hepatitis B virus posttranscriptional regulatory element is composed of two subelements. J Virol. 1996;70:4345–51.